💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Valeant CEO sees new drug pricing environment ahead

Published 2015-10-19, 08:50 a/m
© Reuters.  Valeant CEO sees new drug pricing environment ahead
PSON
-
BHC
-

NEW YORK, Oct 19 (Reuters) - Valeant Pharmaceuticals (N:VRX)
International Inc VRX.TO CEO J. Michael Pearson (L:PSON) said on Monday
that outside pressures are creating a new pricing environment
for all pharmaceutical companies and that Valeant expects to
keep increases to 10 percent or less next year.
During a conference call with investors in which he defended
the company's drug pricing strategy, Pearson said that Valeant
has begun during the past two years to increase sales volumes as
a percentage of growth compared with price increases.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.